Financials in USD. Standardized financial statements.
A compact view of how Aurinia Pharmaceuticals Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $283.06M | $235.13M | $175.51M | $134.03M | $45.60M | $50.12M | $318,000 | $463,000 | $420,000 | $173,000 |
| Revenue Growth? | +20.4% | +34.0% | +31.0% | +193.9% | -9.0% | +15660.4% | -31.3% | +10.2% | +142.8% | 0.0% |
| Cost of Revenue? | $32.66M | $28.25M | $14.15M | $5.66M | $1.09M | $0 | $0 | $41.38M | $1,000 | $4,000 |
| Gross Profit? | $250.39M | $206.88M | $161.37M | $128.37M | $44.51M | $50.12M | $318,000 | -$40.92M | $419,000 | $169,000 |
| Gross Margin? | +88.5% | +88.0% | +91.9% | +95.8% | +97.6% | +100.0% | +100.0% | -8837.8% | +99.8% | +97.7% |
| Operating Expenses? | $145.48M | $211.57M | $253.06M | $239.84M | $225.25M | $154.41M | $91.26M | $56.62M | $47.48M | $22.98M |
| Operating Income? | $104.91M | -$4.69M | -$91.69M | -$111.47M | -$180.74M | -$104.29M | -$90.94M | -$56.16M | -$47.06M | -$22.81M |
| EBITDA? | $127.76M | $31.73M | -$63.05M | -$103.65M | -$177.44M | -$102.92M | -$89.77M | -$53.93M | -$45.61M | -$21.34M |
| Income Before Tax | $114.16M | $7.45M | -$77.47M | -$106.35M | -$180.21M | -$102.77M | -$88.24M | -$64.05M | -$70.79M | -$23.30M |
| Income Tax Expense | -$173.04M | $1.70M | $551,000 | $1.83M | $760,000 | -$94,000 | $144,000 | $73,000 | $0 | $0 |
| Net Income? | $287.20M | $5.75M | -$78.02M | -$108.18M | -$180.97M | -$102.68M | -$88.39M | -$64.12M | -$70.79M | -$23.30M |
| EPS? | $2.14 | $0.04 | $-0.54 | $-0.76 | $-1.40 | $-0.87 | $-1.33 | $-0.76 | $-0.92 | $-0.66 |
| Diluted EPS? | $2.07 | $0.04 | $-0.54 | $-0.76 | $-1.40 | $-0.87 | $-1.33 | $-0.76 | $-0.92 | $-0.66 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality